50.6 F
New York
Friday, December 4, 2020

Russia’s R-Pharm Signs Deal With AstraZeneca [NYSE: AZN] To Develop COVID-19 Vaccine

Must read

Ring [NYSEMKT: REI] Energy Started Drilling Operation In New Horizontal Well

Ring Energy declared that the company has started operations on its new well. The company told that in ten months, it finally initiated...

KKR [NYSE: KKR] Purchased Two Industrial Properties Of Worth $171Million

KKR & Co. Inc. announced that it purchased two properties in texas for distribution purposes. The industrial properties total an area of...

EchoStar [NASDAQ: SATS] Partners With JT And Brings A Single Terminal For Network Connectivity To Market

EchoStar Corp.  declared that it has collaborated with Jersey Telecom so that it can provide its clients in the United Kingdom and Europe...

Capstone [NASDAQ: CPST] Receives An 800Kw Microturbine Order From Costa

Capstone Turbine Corp. declared that it has acquired an order of 800KW microturbine from the Costa Group. The request was obtained by the...

Russian drugmaker R-Pharm has made a deal with a drug maker AstraZeneca to develop a coronavirus vaccine. It has disclosed on Friday that both the companies have signed the contract for the manufacturing of the COVID-19 vaccine which is being developed by the British pharmaceutical giant and Oxford University.

Canada, the US, and Britain earlier accused Russia that it is trying to steal the COVID-19 vaccine and treatment research. But after the deal, Russia’s wealth fund disclosed that Moscow has no need to steal information.

Shares of AstraZeneca soared 1.11% at $58.07 during the trading of Friday. It has a trading volume of 4.89 million as compared to the average volume of 5.41 million. In the past 52-weeks of trading, it has fluctuated between a low of 36.15 and a high of 58.84.

If we turn our focus on the profitability, it has reurn on investment (ROI) of 8.30%, return on equity (ROE) of 12.30% and return on assets (ROA) of 2.50%. This company has Gross Margin of 79.60%, and an Operating Margin of 12.10%, Profit Margin of 6.00%.

Alexey Repik, chairman of the R-Pharm Board said: “We have formalized the project in the area of signed agreements in the field of vaccine development and supply, developed by AstraZeneca and Oxford University.” R-Pharm specializes in research and development and manufacturing of high-tech medicines.

More articles

Latest article

Vodafone [NASDAQ: VOD] and RingCentral signs a partnership to provide next-generation services

Vodafone signed a strategic alliance with Ring Central . The association will modify business connections and alliances. The enterprises have joined hands to...

Salesforce [NYSE: CRM] Enters A Deal To Acquire Slack

Salesforce engages in a contract to buy Slack at a worth of $27.7B. This purchase to build an operating system for the...

Xilinx [NASDAQ: XLNX] Announced That It Acquired Falcon Computing

Xilinx Inc. declared that it has purchased falcon Computing Solutions to make flexible computing more accessible and easily adapted by computer programmers. The...

Luokung Corp. [NASDAQ: LKCO] To Acquire EMG For RMB 836 Million

Luokung Technologies Corp. a location-based service company has agreed to buy EMG technologies for Ren Min Bi  836 million. The company will pay...

Nokia [NYSE: NOK] Extends Collaboration With AT&T to Deliver Seamless IoT Connectivity

Nokia Corp. declared that the company has extended its contract with AT&T . The collaboration among the companies can supply and provide an...

Wendy [NASDAQ: WEN] Strikes A Deal With Rebel Foods To Open 250 Cloud Kitchens.

Wendy’s Co. and Rebel foods have partnered to open about 250 cloud kitchens in India. These kitchens will only serve the customer with...

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...